(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients with T cell lymphoma (TCL).
T-cell lymphoma is a rare cancer that develops in T cells, a type of white blood cell that helps the immune system.
Twenty five patients were enrolled in the study. Out of this, 9 patients (39%) showed objective responses to treatment with soquelitinib, including six complete responses (26%) and three partial responses. Median progression free survival (PFS) was 6.2 months. Additionally, the drug candidate was well tolerated with no new safety signals.
These results will be presented at the 16th Annual T-Cell Lymphoma Forum taking place March 20-22, 2025 in San Diego, CA.
A Phase 3 registrational study of soquelitinib in patients with relapsed Peripheral T cell lymphoma (PTCL) is underway.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
